Intuitive Surgical stock: Single-port robot drives new growth

Published on 11/09/2026 at 13:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Intuitive Surgical stock is under pressure despite strong procedure growth. The Single-Port platform is emerging as a faster-growing driver for the surgical robotics specialist.

Growth broadens beyond flagship systems

Single-Port procedures grew faster than the wider da Vinci platform in fiscal Q3 2026.
Management plans a U.S. submission for the SP vessel sealer in the fourth quarter.
Instrument pricing and competition remain important risks for the recurring-revenue model.

Intuitive Surgical, US46120E6023, Illustration mit AI erstellt.

Intuitive Surgical's growth story is broadening beyond its established da Vinci platform. A Trefis analysis published by Yahoo Finance on November 7 said the company's Single-Port, or SP, robot is expanding faster than its wider surgical robotics portfolio.

SP procedures rose 55% in fiscal third-quarter 2026, compared with 14% growth for overall da Vinci procedures and 31% for the Ion platform, according to the analysis. Intuitive placed a record 42 SP systems during the quarter, taking the SP installed base to 487 systems, up 42% from a year earlier.

Single-Port adds to the growth engine

The SP platform remains a relatively small part of Intuitive's installed base. The 487 systems sit within more than 13,200 da Vinci and Ion systems worldwide, while SP represented 42 of the 546 da Vinci systems placed during the quarter. That limits the platform's immediate contribution to group revenue but gives investors a potential additional source of procedure and instrument growth.

Systems revenue reached 769 million US dollars in fiscal Q3, a 30% increase from the prior-year quarter. The analysis also noted that instruments and accessories accounted for 59.8% of fiscal 2025 revenue, highlighting why utilization of the installed base matters more than equipment placements alone over time. Da Vinci instrument revenue per procedure rose to about 1,860 US dollars from 1,800 US dollars a year earlier, helped by higher SP use and da Vinci 5 instruments.

Pricing remains a central risk

Management expects instrument pricing actions and a policy-driven price cut in China to reduce da Vinci instrument revenue per procedure by 3% to 5% once fully implemented, assuming the product mix remains unchanged. The company said the shift toward SP and da Vinci 5 is not included in that estimate and could support revenue per procedure. Extended-life instruments are scheduled to roll out by country from the first half of 2027.

Management also called the SP vessel sealer a key enabler for broader adoption and plans to submit the device in the United States during the fourth quarter of 2026. The update matters because the SP platform needs sustained procedure growth and a broader product range to offset pricing pressure in the established instrument business.

Stock remains sensitive to execution

Intuitive Surgical's valuation reflects both the durability of its installed-base model and the execution risks around competition, pricing and new system adoption. The Trefis analysis said the shares had lost 17.5% over the preceding twelve months despite revenue growth of 20.5% over the last four quarters. Its conclusion points investors toward instrument revenue per procedure as a key figure to watch when Intuitive reports in January 2027.

The real-time quote of Intuitive Surgical stock was 407.70 euros on Lang & Schwarz at 13:30 CET on Monday, November 9.